Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
McKesson
Baxter
McKinsey
Moodys
Novartis
Chinese Patent Office
US Army
Deloitte
Healthtrust

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,084,802

« Back to Dashboard

Which drugs does patent 9,084,802 protect, and when does it expire?

Patent 9,084,802 protects MINOCIN and is included in one NDA.

This patent has twenty-two patent family members in twenty-one countries.
Summary for Patent: 9,084,802
Title:Tetracycline compositions
Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
Inventor(s): Griffith; David C. (San Marcos, CA), Boyer; Serge (San Diego, CA), Hecker; Scott (Del Mar, CA), Dudley; Michael N. (San Diego, CA)
Assignee: REMPEX PHARMACEUTICALS, INC. (San Diego, CA)
Application Number:14/204,881
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,084,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Rempex Pharms Inc MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING BACTERIAL INFECTIONS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,084,802

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,278,105 Tetracycline compositions ➤ Subscribe
9,744,179 Tetracycline compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,084,802

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 102970992 ➤ Subscribe
Colombia 6650346 ➤ Subscribe
Denmark 2568987 ➤ Subscribe
European Patent Office 2568987 ➤ Subscribe
European Patent Office 3135289 ➤ Subscribe
Spain 2613738 ➤ Subscribe
Hong Kong 1180586 ➤ Subscribe
Hungary E033161 ➤ Subscribe
Israel 222896 ➤ Subscribe
Japan 2013529201 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Julphar
McKesson
Colorcon
Deloitte
Moodys
Healthtrust
Dow
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot